Format

Send to

Choose Destination
Br J Dermatol. 2018 Dec 30. doi: 10.1111/bjd.17538. [Epub ahead of print]

Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis.

Author information

1
National expertise Center for Atopic Dermatitis, department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, the Netherlands.
2
Department of Ophthalmology, University Medical Center Utrecht, Utrecht, the Netherlands.
3
Department of Dermatology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
4
Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, the Netherlands.
5
Department of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands.

Abstract

Higher rates of conjunctivitis have been reported in atopic dermatitis (AD) patients treated with dupilumab, an anti-interleukin (IL)-4Rα antibody inhibiting IL-4 and IL-13, compared to patients treated with placebo.1 However, the exact pathomechanism has not been clarified. Given the necessity of optimal treatment and risk management, the aim of this study was to describe the histopathological characteristics of conjunctivitis during dupilumab treatment in AD patients. This article is protected by copyright. All rights reserved.

PMID:
30597515
DOI:
10.1111/bjd.17538

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center